PURPOSE: Colorectal cancer is an important cause of cancer deaths. Here, we focused our investigation on the beta-catenin gene which is implicated in colorectal carcinogenesis and tested whether beta-catenin mRNA is detectable in the plasma of colorectal carcinoma and adenoma patients using quantitative reverse transcriptase-PCR. EXPERIMENTAL DESIGN: Plasma beta-catenin mRNA was measured from 58 colorectal carcinoma patients, 49 colorectal adenoma patients, and 43 apparently normal subjects using intron-spanning primers and Taqman probes. Five clinicopathological parameters were studied and correlated with plasma beta-catenin mRNA concentration. Additionally, 19 colorectal carcinoma patients after tumor removal were also recruited for plasma beta-catenin mRNA measurement to further demonstrate the clinical usefulness of this test. RESULTS: beta-catenin mRNA was detected with median concentrations of 8737 (range: 1480-933100), 1218 (range: 541-2254) and 291 (range: 0-1366) copies/ml plasma in colorectal carcinoma, colorectal adenoma, and apparently normal subjects, respectively. Statistical analysis demonstrated that plasma beta-catenin mRNA concentration was correlated to tumor stage but not sex, age, lymph node status, and degree in differentiation. Moreover, plasma beta-catenin mRNA concentration decreased significantly after tumor removal in 16 of 19 (84%) colorectal carcinoma patients. CONCLUSIONS: We conclude that plasma beta-catenin mRNA may potentially serve as a marker for colorectal cancer.
PURPOSE:Colorectal cancer is an important cause of cancer deaths. Here, we focused our investigation on the beta-catenin gene which is implicated in colorectal carcinogenesis and tested whether beta-catenin mRNA is detectable in the plasma of colorectal carcinoma and adenomapatients using quantitative reverse transcriptase-PCR. EXPERIMENTAL DESIGN: Plasma beta-catenin mRNA was measured from 58 colorectal carcinomapatients, 49 colorectal adenomapatients, and 43 apparently normal subjects using intron-spanning primers and Taqman probes. Five clinicopathological parameters were studied and correlated with plasma beta-catenin mRNA concentration. Additionally, 19 colorectal carcinomapatients after tumor removal were also recruited for plasma beta-catenin mRNA measurement to further demonstrate the clinical usefulness of this test. RESULTS:beta-catenin mRNA was detected with median concentrations of 8737 (range: 1480-933100), 1218 (range: 541-2254) and 291 (range: 0-1366) copies/ml plasma in colorectal carcinoma, colorectal adenoma, and apparently normal subjects, respectively. Statistical analysis demonstrated that plasma beta-catenin mRNA concentration was correlated to tumor stage but not sex, age, lymph node status, and degree in differentiation. Moreover, plasma beta-catenin mRNA concentration decreased significantly after tumor removal in 16 of 19 (84%) colorectal carcinomapatients. CONCLUSIONS: We conclude that plasma beta-catenin mRNA may potentially serve as a marker for colorectal cancer.
Authors: Ulrike Stein; Susen Burock; Pia Herrmann; Ina Wendler; Markus Niederstrasser; Klaus-Dieter Wernecke; Peter M Schlag Journal: J Mol Diagn Date: 2011-03 Impact factor: 5.568
Authors: Siu Tim Cheung; Chi Leung Liu; Jeremy P H Chow; Yuk Ting Lee; Ying Chi Ip; Jenny C Y Ho; Sheung Tat Fan Journal: Neoplasia Date: 2006-09 Impact factor: 5.715
Authors: N Mohammed; M Rodriguez; V Garcia; J M Garcia; G Dominguez; C Peña; M Herrera; I Gomez; R Diaz; B Soldevilla; A Herrera; J Silva; F Bonilla Journal: Oncol Lett Date: 2011-04-28 Impact factor: 2.967
Authors: Vanesa Garcia; Jose M Garcia; Javier Silva; Cristina Peña; Gemma Dominguez; Yolanda Lorenzo; Raquel Diaz; Isabel Alonso; Antonio Colas; Alicia Hurtado; Antonio Sanchez; Felix Bonilla Journal: J Cancer Res Clin Oncol Date: 2008-05-07 Impact factor: 4.553